Unlocking new molecular mechanisms and potential therapeutic targets for chronic lymphocytic leukemia by Bojnik, Engin
  
      
 
 
Università degli Studi di Padova 
 
DIPARTIMENTO DI SCIENZE CHIRURGICHE ONCOLOGICHE E 
GASTROENTEROLOGICHE – DISCOG 
 
 
CORSO DI DOTTORATO DI RICERCA IN: ONCOLOGIA E ONCOLOGIA CHIRURGICA 
Ciclo di dottorato XXIX 
 
 
 
 
 
Unlocking new molecular mechanisms and potential therapeutic 
targets for chronic lymphocytic leukemia 
 
 
 
 
 
Coordinatore: Prof. Paola Zanovello 
Supervisore: Prof. Anita De Rossi 
Co-Supervisore: Prof. Paolo Ghia 
 
 
            Dottorando: Engin Bojnik 
          
 
2 
 
TABLE OF CONTENTS 
 
I. GENERAL INTRODUCTION ..................................................................................... 5 
1. Chronic Lymphocytic Leukemia .......................................................................... 5 
2. Prognosis ............................................................................................................. 6 
3. Chromosomal abnormalities. ................................................................................ 8 
4. 13q14 Deletion..................................................................................................... 8 
II. CHAPTER ONE .......................................................................................................... 10 
Role of miR-15a/miR-16-1 and TP53 axis in regulation of telomerase in CLL 
1. Introduction ..................................................................................................... 10 
 Telomere and telomerase ........................................................................ 10 
 Telomere and telomerase in CLL ............................................................ 11 
 The tumor suppressor gene TP53 and telomerase interaction ................... 12 
 MicroRNA-15a and microRNA-16-1 mediated regulation of TP53 in 
CLL ........................................................................................................ 13 
2. Aims .................................................................................................................. 14 
3. Materials and methods .................................................................................... 15 
 Patients ................................................................................................... 15 
 Fluorescence in situ hybridization ........................................................... 15 
 Primers, probes and standard curve construction for the quantification of 
hTERT transcripts ................................................................................... 16 
 Quantification of TP53 transcripts ........................................................... 16 
 Evaluation of miRNAs Expression .......................................................... 17 
 Statistical analysis ................................................................................... 18 
4. Results .............................................................................................................. 19 
 Relative miR-15a and miR-16-1 and TP53 mRNA levels in CLL with or 
without 13q14 deletion ............................................................................ 19 
 High TP53 levels are associated with reduced levels of miR-15a and miR-
16-1 ........................................................................................................ 21 
 Relationship between TP53 and TERT levels .......................................... 22 
 Correlations with the percentage of 13q14 deletions detected by FISH .... 24 
 Prognostic value of TERT and TP53 levels in CLL ................................. 25 
5. Discussion ......................................................................................................... 30 
 
3 
 
III. CHAPTER TWO ......................................................................................................... 32 
Targeting MEK/ERK pathway as a novel therapeutic prospective in CLL 
1. Introduction ..................................................................................................... 32 
 B cell receptor complex .......................................................................... 32 
 BCR signaling in CLL ............................................................................ 33 
 MAPKs pathway ..................................................................................... 34 
 MEK1/2 .................................................................................................. 34 
 ERK1/2 ................................................................................................... 34 
 MEK1/2 inhibitors .................................................................................. 35 
 Small-molecule inhibitors of BCR signaling ........................................... 36 
 B Cell Anergy ......................................................................................... 37 
2. Aims .................................................................................................................. 39 
3. Materials and methods .................................................................................... 40 
 Tissue samples and cell purification ........................................................ 40 
 Cell lines and Cell culture and inhibitors ................................................. 40 
 Western blot analysis and antibodies ....................................................... 41 
 Analysis of cell viability and apoptosis ................................................... 41 
 Nucleofection of MEC1 cell line ............................................................. 42 
 RNA extraction and real-time polymerase chain reaction ........................ 42 
 Cell synchronization ............................................................................... 42 
 Cell-cycle analysis .................................................................................. 43 
 Purification, adoptive transfer and culture of TCL1 leukemias ................ 43 
 Statistical analysis ................................................................................... 43 
4. Results .............................................................................................................. 44 
 Investigating the MEK/ERK inhibitor Trametinib in leukemia and 
lymphoma cell lines ................................................................................ 44 
 Transfection experiments with siMEK1 and siMEK2 .............................. 46 
 Relationship between ERK and MEK activation in human primary CLL 
cells ........................................................................................................ 48 
 Impact of ERK inhibition on human primary CLL cells: relationship with 
ERK phosphorylation .............................................................................. 49 
 MEK inhibition in purified normal B cells .............................................. 52 
 Combined ERK and BTK inhibition in vitro ........................................... 53 
4 
 
 Cell cycle analysis .................................................................................. 55 
 In vivo activity of Trametinib in TCL1 transgenic mouse model of CLL . 56 
5. Discussion ......................................................................................................... 60 
IV. SUMMARY ................................................................................................................. 62 
V. REFERENCES ............................................................................................................ 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
GENERAL INTRODUCTION 
 
1. Chronic Lymphocytic Leukemia 
Chronic lymphocytic leukemia (CLL) represents the most common leukemia in the Western 
world. It has an age-adjusted incidence rate of 4.5 per 100,000 inhabitants in the United 
States and a median age at diagnosis of ~70 years (Fabbri and Dalla-Favera, 2016). CLL is 
a malignancy of B-lymphocytes that accumulate in the blood, bone marrow and other 
lymphoid tissues, and is diagnosed in the presence of ≥5,000 clonal B-lymphocytes per 
microlitre of peripheral blood persisting for more than 3 months. It is characterized by a 
neoplastic clonal expansion of CD5+ morphological mature B-lymphocytes (Zenz et al, 
2010). CLL patients has variable clinical course with overall survival times ranging from 
months to decades. Some patients have no or minimal signs and symptoms during their 
entire disease course and have a survival time similar to age-matched controls. Other 
patients experience rapidly deteriorating blood counts and suffer from symptoms at 
diagnosis or soon thereafter necessitating therapy. Despite recent major advances in our 
knowledge of the pathogenesis and in the management of CLL, relapse ultimately occurs in 
almost all patients who require therapy and the disease remains incurable (Hallek and 
Pflug, 2010).  
 
Figure 1. CLL in the peripheral blood. Marked lymphocytosis is seen; lymphocytes have scant 
cytoplasm, clumped “soccer ball” chromatin, round nuclei, and indistinct nucleoli.  
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2. Prognosis 
CLL patients can be very heterogeneous in terms of clinical outcome with some patients 
showing a life expectancy similar to unaffected individuals with no or delayed need for 
therapies, while others experience a more aggressive form of the disease with a shorter 
survival time and early treatment requirements (Zenz et al, 2010). A third population of 
patients has a disease course and a survival expectancy between these two extremes. 
 
Figure 2. An illustration of the most important genetic and protein based prognostic markers in 
relation to the clinical outcome of CLL. 
 
The standard clinical procedures to estimate prognosis are the clinical staging systems 
developed by Rai and Binet (Rai et al, 1975; Binet et al, 1981). These systems define early 
(Rai 0, Binet A), intermediate (Rai I/II, Binet B) and advanced (Rai III/IV, Binet C) stage 
disease with median estimated survival times of > 10, 5–7, and 1–3 years, respectively. 
However, there is heterogeneity in the course of the disease among individual patients 
within a single stage group. Several important observations related to the biologic 
significance of immunoglobulin mutational status, ZAP-70 overexpression, chromosomal 
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aberrations and CD38 expression have led to the ability to identify patients at high risk for 
early disease progression (Kröber et al, 2002; Damle et al, 1999; Hamblin et al, 1999; 
Döhner et al, 2000).  
The presence or the absence of somatic mutations of the Immunoglobulin Heavy Variable 
(IGHV) genes in CLL cells correlates with different clinical courses and outcomes 
(Hamblin et al, 1999; Damle et al, 1999). A ≥98% identity of the expressed IGHV gene 
with the corresponding germline sequence (unmutated CLL) is associated with a more 
aggressive disease and a shorter median survival time as compared to mutated cases.  
 
Figure 3. Pathogenesis of CLL subsets. The two major subsets (unmutated U-CLL and mutated M-
CLL) and the isotype-switched variant derive from three different normal B-cell populations with 
no interconversion (Stevenson et al, 2011). 
 
CD38 expression on the cell surface of CLL cells, is also associated with a more aggressive 
disease. CD38 positive CLL cases have a shorter time to progression and shorter survival 
(Damle et al, 1999). Gene expression profiling revealed that ZAP70 mRNA is expressed in 
some CLL cases (Scielzo et al, 2006). ZAP70 expression in >20% of the leukemic cells 
carries an adverse prognostic value (Crespo et al, 2003). Initially, ZAP70 was reported as a 
reliable surrogate for IGHV gene mutation status, as expression of ZAP70 appeared to 
correlate with U-CLL cases, but later it became apparent that its prognostic value is 
independent of the mutational status. 
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3. Chromosomal abnormalities.  
CLL cells carry several recurrent genomic alterations, detectable by Fluorescent In Situ 
Hybridization (FISH). In contrast to other lymphoproliferative disorders, recurrent 
translocations are not present, while the most typical aberrations lead to loss or gain of 
genetic material. Some aberrations appear during the course of the disease whereas others 
can be present very early in the natural history if the disease. Overall, different alterations 
can be found in up to 80% of CLL cases. More than 50% of the cases show only a single 
abnormality, 20% carry two and about 10% more than two aberrations (Dohner et al, 2000). 
 
Figure 4. Patients with certain chromosomal aberrations such as del(17p) or del(11q) have an 
inferior prognosis compared with patients with trisomy 12, normal karyotype, or del(13q) (Döhner  
et al, 2000). 
 
Del13q14 is the most frequent alteration (Cimmino et al, 2005) and it associates with a 
favorable clinical course of the disease. On the contrary, the most deleterious aberrations are 
deletions at 17p (leading to the loss of TP53 gene) and deletions at 11q (associated with 
reduced ATM expression) correlating with short median survival. Trisomy of chromosome 
12 does not significantly affect survival as compared to normal karyotype (Malek et al, 
2013). 
 
4. 13q14 Deletion 
Deletion of 13q14 region, found in more than 50% of CLL patients, is the most common 
cytogenetic abnormality and has been associated with good prognosis. Several studies have 
9 
 
revealed some insights in the candidate genes located at 13q that could be responsible for 
CLL pathogenesis, as well as in the prognostic heterogeneity of 13q-deleted patients. With 
regard to biologic basis underlying 13q deletions, miR-15a and miR16-1, located in the 
minimal deleted region (MDR), have been described to exhibit a tumoral suppressor 
function in CLL (Klein et al, 2010). Besides these microRNAs, other genes located in 13q, 
such as DLEU7, could cooperate in the tumoral suppressor activity. In addition, it has been 
extensively demonstrated that large 13q losses involving RB1 gene are related to shorter 
overall survival than those small deletions encompassing only miR-15a and miR16-1 (Calin 
et al, 2002). 
In contrast to other recurrent abnormalities in CLL, the presence of biallelic losses in 13q 
has been described in nearly 30% of 13q-deleted CLL patients (Reddy et al, 2006). The size 
of the abnormal clone detected by FISH is variable in CLL patients. It has been described 
that patients with a higher percentage of altered nuclei have a significantly shorter overall 
survival. The optimal cut-off point that defines a poorer outcome of 13q deletion differs 
between 65.5% to 90% (Hernandez et al, 2009; Dal Bo et al, 2011; Orlandi et al, 2013). 
Thus, CLL patients with isolated 13q deletion can be risk-stratified according to the 
percentage of altered cells by FISH. 
Interestingly, deregulation of many relevant cellular pathways has also been shown in those 
patients with higher percentages of 13q deletion. Among them are remarkably the 
deregulation of several important miRNAs and overexpression of genes mainly involved in 
B-cell receptor signaling (e.g., SYK and CD79b), NFκB signaling and prosurvival and 
antiapoptotic pathways (e.g., Wnt and RAS signaling (Rodriguez et al, 2012). 
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CHAPTER ONE 
Role of miR-15a/miR-16-1 and TP53 axis in regulation of telomerase in CLL 
 
 
1. INTRODUCTION 
Telomere and telomerase 
Human telomeres are DNA-protein structures consisting of G-rich repeats (TTAGGG), 
which protects the end of the chromosome from deterioration or from fusion with 
neighboring chromosomes (Bryan and Englezou, 1995). Telomeres are shortened by 
approximately 50-100 base pairs per cell division in humans (Allsopp and Vaziri, 1992). 
Defects in telomere length have been implicated in the pathology of several age related 
diseases and premature ageing syndromes, as well as in cancer (Blasco, 2005). Human 
cancer cells have been shown to maintain average telomere length over time (Englezou et 
al. 1998). Human cancer cells appear to have extremely short class of telomeres (Xu and 
Blackburn 2007). 
Telomerase is the enzyme responsible for the maintenance of telomeres. Human telomerase 
is a ribonucleoprotein, consisting of both a protein catalytic subunit, the telomerase reverse 
transcriptase (hTERT), and an RNA component (hTR) (Lingner et al, 1997). Telomerase is 
able to synthesize new telomeric repeats onto the 3’-end leading stand after DNA 
replication, allowing for the conventional DNA replication machinery to elongate the 5’-end 
lagging strand, using the newly extended 3’-end leading strand as a template.  Of the two 
minimal catalytic components of the telomerase hTERT is the limiting component for 
telomerase activity (Feng et al, 1995) and telomerase activity closely correlates with 
hTERT expression (Cong et al, 1999).  
Telomerase expression has been found to be up-regulated in approximately 90% of human 
cancers, which enables the continued and uncontrolled proliferation of the malignant cells 
that drive tumor growth and progression (Masutomi et al, 2005).  Reactivation of 
telomerase in mortal cells stabilizes their telomeres and provides the cell with unlimited 
proliferative potential (Vaziri and Benchimol 1998). The role of telomerase in 
tumorigenesis is thought to involve the stabilization of critically short telomeres, which 
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occurs after normal cells have experienced genetic instability and survived an escape from 
growth arrest similar to crisis. One characteristic of cancer cells is the acquisition of 
limitless replicative potential (Hanahan and Weinberg 2000) and telomerase activity is 
ultimately required for tumor immortalization (Huang et al. 2004). 
 
Telomere and telomerase in CLL 
Several studies have focused on the potential prognostic significance of telomere and 
telomerase interplay in CLL. In hematological malignancies, the shortening of telomere 
length is accelerated under the increased proliferation pressure and maintained at a short 
length (Aalbers et al, 2013). Significantly shortened telomeres, activation of telomerase and 
modulation of the expression of telomere-associated proteins are correlated with faster 
disease progression, reduced response to chemotherapy, and poor prognosis (Wang et al, 
2010). In CLL patients with high-risk genomic aberrations, (11q or 17p deletions) telomeres 
are extremely shortened, independently of the stage of disease (Britt-Compton et al, 2012). 
Short telomere length in CLL patients is in line with other classical biological factors of 
CLL, including unmutated immunoglobulin, CD38 and ZAP-70 positivity (Roos et al, 
2008). CLL patients with shorter telomere length experienced worse clinical outcomes 
including shorter progression-free survival and overall survival. Thus telomere length was 
indicated as a negative prognostic factor in CLL (Counter et al, 1995; Sellmann et al 
2011). The expression levels of telomere binding proteins (TRF1, RAP1 and POT1) were 
reported to be altered in CLL cells (Poncet et al, 2008). Increased expression of hTERT and 
activation of telomerase are universally involved in oncogenesis and the progression of 
hematopoietic malignancies.  
Telomerase activity, hTERT levels and telomere length were all investigated in CLL 
patients. High telomerase activity is a predictor of a shorter survival in CLL (Bechter, et al 
1998). It has been also reported that, poor prognosis Ig-unmutated CLL subgroup has higher 
telomerase activity, as compared with an Ig-mutated subgroup (Damle et al, 2004). 
Moreover, CLL patients expressing  high hTERT levels have significantly shorter survival 
than hTERT negative CLL patients, regardless of disease stage (Tchirkov et al, 2004). 
We have previously shown that high levels of hTERT and short telomere length were 
associated with a poor clinical outcome of CLL patients (Rampazzo et al, 2012). The 
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poorest prognosis was found in the group with high hTERT levels and short telomeres, 
whereas CLL with low hTERT levels and long telomeres had a more indolent clinical 
behavior. We have also showed that most of the CLL cases with 13q14 deletions have lower 
levels of hTERT when compared to CLL patients with other chromosomal abnormalities 
(Rampazzo et al, 2012).  
 
The tumor suppressor gene TP53 and telomerase interaction 
The tumor suppressor gene TP53 is a sequence-specific transcription factor that can mediate 
many downstream effects such as growth arrest and apoptosis through activation or 
repression of its target genes. The TP53 gene is mutated in a number of hematologic 
malignancies but the frequency of mutations tends to be low in most lymphoid malignancies 
and in CLL (Rossi et al, 2009).  TP53 mutations represent strong predictors of poor survival 
and refractoriness in CLL and they have a well-established clinical relevance and direct 
implications for the management of CLL (Dohner et al, 1995).  
Telomerase enzymatic activity can be regulated at multiple levels, including alternative 
splicing, chaperone-mediated folding and nuclear translocation; however, the major control 
mechanism of telomerase regulation seems to be at the level of hTERT transcription (Kyo 
and Inoue, 2002).  Several studies correlated the TP53 and telomerase activity during 
carcinogenesis. Telomerase and TP53 are frequently associated with human cancers, and 
activation of telomerase and inactivation of TP53 is involved in cancer cell immortalization. 
For example, overexpression of wild-type TP53 was shown to down-regulate telomerase 
enzymatic activity in a number of cancer cell lines independent of its effects on growth 
arrest and apoptosis (Kamusoto et al, 1999). This observation was attributed to 
transcriptional repression of hTERT by wild-type TP53 since it was preceded by down-
regulation of hTERT mRNA (Kamusoto et al, 1999). This conclusion was supported by 
promoter activity studies demonstrating the ability of TP53 to repress hTERT promoter-
reporter constructs. In an additional study, activation of exogenous temperature-sensitive 
TP53 in BL41 Burkitt's lymphoma cells triggered rapid down-regulation of hTERT mRNA 
expression independent of the induction of the TP53 target gene p21 (Xu et al, 2000). 
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MicroRNA-15a and microRNA-16-1 mediated regulation of TP53 in CLL 
MicroRNAs (miRNAs) are short noncoding RNAs that regulate gene expression (Eulalio et 
al, 2008; Pillai et al, 2007). MiRNAs represent one of the major regulatory family of genes 
in eukaryotic cells by inducing translational repression and transcript degradation (Lim et 
al, 2005; Pillai et al 2007). MiRNA profiles can distinguish normal B cells from malignant 
CLL cells and have been associated with prognosis, progression, and drug resistance in CLL 
patients (Ferracin et al, 2010).  It has been shown that, a cluster of two microRNA genes, 
miR-15a and miR-16-1, was located within the 13q14.3 deleted region (Calin et al, 2002). 
Since 13q14 deletion is the most frequent genomic aberration in CLL, miR-15a/16-1 
expression was found downregulated in ~66% of CLL cases (Calin et al, 2002). The 
importance of miR-15a/16-1 was confirmed also in mouse model of CLL. A point mutation 
causing a decrease in miR-16-1 expression in lymphoid tissues lead to elevated levels of 
antiapoptotic protein Bcl-2 (Raveche et al, 2007). MiR-15a/16-1 and BCL2 expression 
levels were found inversely correlated in CLL, and downregulation of these microRNAs in 
leukemic cell lines resulted in an increase of Bcl2 expression with consequent inhibition of 
apoptosis (Cimmino et al, 2005). Moreover, microarray experiments performed on CLL 
patients with high vs low levels of miR-15a/16-1 identified a gene signature which also 
contains MCL1, an antiapoptotic BCL-2 family member associated with B-CLL cell 
survival and chemotherapy resistance (Calin et al, 2007). More importantly, it has been also 
shown that, the tumor suppressor protein TP53 is directly regulated by miR-15a/miR-16-1 
in CLL. The loss of miR-15a/miR-16-1 expression, represented by CLLs with 13q 
deletions, not only shifts the balance toward higher levels of the BCL2 and MCL 1, but also 
toward higher levels of the TP53 (Fabbri et al, 2011). TP53 represented the molecular link 
between the miR-15a/miR-16-1 clusters. Consequently, in patients with CLLs with 13q 
deletions, while the number of apoptotic cells may decrease because of the increased levels 
of antiapoptotic proteins, the TP53 tumor suppressor pathway remains intact, thus keeping 
the increase in tumor burden relatively low. 
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2. AIMS 
 
Several studies have focused on the potential prognostic significance of telomerase 
(TERT) in CLL. We previously showed that most of the CLL cases with 13q14 
deletion have lower levels of TERT than CLL with other chromosomal 
abnormalities. miR-15a and miR-16-1, targets of 13q14 deletion in CLL; may 
directly down-regulate tumor suppressor protein TP53 which is known to be an 
important negative regulator of telomerase. Based on these evidences, we 
hypothesized that, in patients with del13q, low TERT levels may be a consequence of 
the loss of miR-15a and miR-16-1 that in turn regulate TP53 levels. Following this 
reasoning, during my PhD studies we aimed at determining the miR-15a/mi-R16-1 
levels in CLL patients with or without the 13q14 deletion and correlate them to 
both TP53 and TERT transcripts. 
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3. MATHERIALS AND METHODS  
 
Patients 
Peripheral blood cells were collected from 155 CLL patients who attended the Haematology 
Section, Clinical and Experimental Medicine, University of Padova. This study included 99 
CLL with the 13q14 deletion as the sole chromosomal abnormality detected by fluorescence 
in situ hybridization (FISH), and 56 CLL with no chromosomal abnormalities detected by 
FISH (i.e., 13q14.3, 17p13.1[TP53], and 11q22.3[ATM] deletions, and trisomy 12). CLL 
cases with TP53 mutations were excluded from this study. The median (interquartile) ages 
of patients with CLL with normal cytogenetcs profile and with the sole 13q14 deletion were  
68 (60-75) and 70 (63-76) years, respectively (p=0.342). All samples were collected at the 
time of diagnosis, and all patients were untreated at the time of sampling. IGVH gene status 
was assessed as previously described (Terrin et al, 2007). The percent of IGVH unmutated 
cases did not statistically differ between the two groups (21% vs 23%; p=0.517). The 
median (interquartile) follow-up time from blood sampling was 55 (27-96) months. Time 
from diagnosis to first treatment (TTFT) was considered as a marker for time to disease 
progression. Informed consent was obtained according to the Helsinki declaration and the 
study was approved by the local Ethics Committees. 
 
Fluorescence in situ hybridization  
Fluorescence in situ hybridization (FISH) was performed on standard cytogenetic 
preparations from peripheral blood. The slides were hybridized with the multicolour probe 
sets LSI p53/LSI ATM and LSI D13S319/LSI 13q34/ CEP12 (Vysis-Abbott, Des Plaines, 
IL, USA) according to the manufacturer’s protocol. Three hundred interphase nuclei were 
analyzed for each probe. The cut-off for positive values (mean of normal control ±3 
standard deviation) determined from ten cytogenetically normal samples was 4% for 
centromere 12 trisomy (+12), and 10% for del 11q22.3(11q-), del13q14.3 (13q-) and del 
17p13.1 (17p-). The B-CLL cases with 11q- or 17p- and 13q- (n=12) were included in the 
group of 11q-,17p-. 
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Primers, probes and standard curve construction for the quantification of hTERT 
transcripts  
To quantify the mRNA of hTERT, set of AT primers were designed. The forward primer 
AT1 (5'-CGGAAGAGTGTCTGGAGCAA-3') and the reverse primer AT2 (5'-
GGATGAAGCGGAGTCTGGA-3') bind to nucleotide sequences  nt 1784-1803  and nt 
1904-1926, respectively, (Genbank accession number: AF015950), located upstream of the 
RT motif 1 of the hTERT gene. Amplification with AT1 and AT2 primers allowed the 
detection of all hTERT transcripts. The fluorogenic probes AT (FAM 5'-
TTGCAAAGCATTGGAATCAGACAGCAC-3' TAMRA), which recognize sequences 
located within the products amplified by AT1/AT2 primer pairs, were synthesized by PE 
Applied Biosystems. The standard reference curve to quantitate hTERT-AT transcripts was 
performed  using serial 5-fold dilutions of the hTERT amplicon we constructed as follows: 
RNA from BL41 cells, strongly expressing the hTERT gene, was  extracted and 
retrotranscribed as described above, and cDNA was amplified using primers F (5'-
ATGTCACGGAGACCACGTTT-3') and R (5'-AGAGCAGCGTGGAGAGGAT-3') which 
bind to nucleotide sequences located upstream and downnstream, respectively, of regions 
recognized by AT1/AT2 primer pairs. Amplification was performed in a 50 μl mixture 
containing 1μl Taq Gold (5 U/μl; Applied Biosystems), 5 μl Buffer 10X (500 mM KCl, 
100mM Tris-HCl, pH 8.3), 3μl MgCl2 (25mM), 200μM dNTP, and 35 pmol of each F and R 
primer, and carried out for 35 cycles, each consisting of 30 sec at 95°C, 30 sec at 60°C, and 
30 sec at and 72°C, in a thermal cycler (9600 Perkin Elmer). The amplicon of 840 bp was 
run on an agarose gel, purified by using NucleoSpin Extract kit (M-Medical) according to 
the manufacturer's instructions, and quantified by spectrophotometer.  
 
Quantification of TP53 transcripts 
The standard reference curve for quantifying TP53 transcripts was performed using serial 5-
fold dilutions of the TP53 amplicon, constructed as follow: one microgram of total RNA 
extracted from EHEB cell line, expressing wild type TP53, was retro-transcribed into cDNA 
using the SuperScript TM III RNase Reverse Trancriptase assay (Invitrogen) according to 
the manufacturer's instructions. The amplicon of 108 bp was run on an agarose gel, purified 
by using NucleoSpin Extract kit (M-Medical) according to the manufacturer's instructions, 
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and quantified by spectrophotometer. Then the cDNA (50ng/10uL) of both samples and 
reference curve, were amplified in real-time PCR  with the same kit (TaqMan Gene 
Expression Assay - Human TP53: Hs01034249_m1 - LifeTechnologies). In particular, 
amplification of TP53 transcripts was performed in a 20 μl mixture containing 0,25 μl Taq 
Gold (5 U/μl; Applied Biosystems), 2,5 μl Buffer 10X, 1,5 μl MgCl2 (25mM), 2 uL dNTPs 
mix (10mM), and 3,5 uL of TaqMan Gene Expression Assay - Human TP53 kit (20X), and 
carried out for 40 cycles, each consisting of 30 sec at 95°C, 30 sec at 55°C, and 1 min at and 
72°C, in a thermal cycler (9600 Perkin Elmer). To normalize TP53 transcripts for the 
amount of total RNA, 10 μL cDNA from each sample was amplified for the housekeeping 
gene GAPDH, then values of TP53 were normalized for 10
5
 copies of GAPDH.  
 
Evaluation of miRNAs Expression 
Reverse transcription (RT) 
cDNA for measuring the expression of miR-15a, miR-16-1 and the reference housekeeping 
gene small nuclear RNA-U6 (RNU6B) was obtained from 15 ng of total RNA available for 
101 patients. For each miRNA a specific reverse transcription (RT) was performed 
according to the manufacturer’s instructions using the TaqMan® MicroRNA Reverse 
Transcription Kit (Thermo Fisher Scientific) and specific stem-loop RT primers contained 
in TaqMan® MicroRNA Assays (Thermo Fisher Scientific). Each specific RT reaction for 
each miRNAs contains 1,5 uL of 10X Buffer, 0,15 uL of dNTPs mix (100mM), 1 uL of 
Multiscribe RT enzime (50U/uL), 0,2 RNase Inhibitor (20U/uL), 7,65 uL of RNase free 
water, 0,5 uL of specific RT-primer and 3 uL (15ng) of RNA in a final volume of 20 uL. 
Each RT reaction was carried out in a thermal cycler (9600 Perkin Elmer) with the 
following conditions: 30 min at 16°C, 30 min at 42°C and 5 min at 85°C. 
 
qRT-PCR 
The qRT-PCR assay for miRNAs expression was performed in a total reaction volume of 20 
μL and contained 7.67 μL of nuclease-free water, 10 μL of TaqMan® Universal PCR 
Master Mix, No AmpErase® UNG (Life Technologies), 1 μL of a TaqMan® MicroRNA 
Assays probe specific for each microRNA (Life Technologies), and 1.33 μL of cDNA 
generated by reverse transcription. Amplifications were performed under the following 
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conditions: 95 °C for 10 min, 50 cycles 95 °C for 15 s and 60 °C for 1 min. The relative 
expression of miR-15a and miR-16-1 was determined by the 2-ΔCt  method. Normalized 
miR-15a and miR-16-1 expression values for individual patients were calculated as follows: 
ΔCt miR-15a = Ct miR-15a – Ct RNU6B; ΔCt miR-16-1 = Ct miR-16-1 – Ct RNU6B and 
normalized expression values = 2-ΔCt. The final normalized miR-15a and miR-16-1 
expression values for individual patients were expressed as the mean values calculated from 
three technical repeats. 
 
Statistical analysis  
The distribution of  continuous variables, such as TERT  and TP53 levels were compared by 
the  Kruskal–Wallis nonparametric test, and the associations between categorical variables 
were analysed by the x2 test. Spearman’s r coefficient (rs) was used for correlations. For 
each variable, TTFT analysis was performed using the Kaplan-Meier method and compared 
by the log-rank test. hTERT levels and telomere length were analyzed as dichotomous 
variables (cut-off: ≤median or <median). Hazard ratios for each category were estimated 
using univariate Cox proportional hazards models with low risk as the reference class. The 
independent role of TERT/TP53 level profile in predicting TTFT was tested using a Cox 
proporzional hazard model. All tests were two-sided, and a p<0.05 was considered 
statistically significant. Statistical analyses were carried out using SAS version 9.1 (SAS 
institute, Cary, NC, USA). 
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4. RESULTS 
 
Relative miR-15a and miR-16-1 and TP53 mRNA levels in CLL with or without 13q14 
deletion 
Since it has been shown that CLL patients with 13q14 deletion lack miR-15a and miR-16-1, 
our first goal was to examine the relative levels of these miRNA’s in our CLL cohort, which 
was consisting of 13q14 deleted (13q14del) and CLL with no any chromosomal 
abnormalities (no FISH abnormalities). We observed that levels of both miR-15a (p=0.009 ) 
and miR-16-1 (p=0.001) were significantly lower in 13q14del CLL than in CLL with no 
FISH abnormalities. The median relative levels of miR-15a and miR-16-1 in 13q14del CLL 
was 1.97 (ranged between 1.23 – 3.34) and 0.15 (ranged between 0.13-0.31), respectively 
(Figure 5A and 5B). Instead in CLL patients without chromosomal abnormalities had higher 
miR-15a  and miR-16-1 median values,  2.86 (ranged between 1,90-4.66) and 0.25 (ranged 
between 0.17-0.37), respectively.  
 
It has been shown that miR-15a and miR-16-1 over-expression in primary CLL cells with 
13q14 deletion is associated with a decrease in TP53, both at mRNA and protein levels. To 
speculate that expression of  TP53 is lower due to loss of miR-15a and miR-16-1 because of 
the deletion in chromosome 13q14, we quantified TP53 mRNA levels in CLL cases with or 
without 13q14 deletion.  
 
TP53 mRNA levels were measured by RT-qPCR in 13q14del and in CLL without any FISH 
abnormalities. None of the analyzed samples had TP53 mutation or deletion. We found that 
TP53 levels were significantly higher in 13q14del CLL than in CLL with no chromosomal 
abnormalities (p=0.012), with median values of 782 [416-1186] vs 582 [304-815] 
copies/10
6
 GAPDH copies, respectively (Figure 5C).  
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Figure 5. Relative levels of A) miR-15a, and B) miR-16-1 in CLL with no FISH abnormalities or 
with 13q14 deletion (13q14del). C) Relative levels of TP53 in CLL with no chromosomal 
abnormalities or with 13q14 deletion (13q14del). Boxes and whiskers represent 25-75th and 10-
90th percentiles, respectively; median is the central line in each box. 
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High TP53 levels are associated with reduced levels of miR-15a and miR-16-1 
Given that miR-15a and miR-16-1 are encoded at 13q14 and are known to target TP53 
mRNA, we related TP53 mRNA levels to miR-15a and miR-16-1 levels in CLL patient with 
13q14 deletion. As predicted, the levels of TP53 mRNA significantly and inverse correlated 
with the levels of miR-15a (rs=   -0.775, p<0.0001, Figure 6A) and miR-16-1 (rs= -0.722, 
p<0.0001, Figure 6B).   
 
Figure 6. Relationship between TP53 levels and A) miR-15a, B) miR-16-1 in 13q14del CLL and C) 
miR-15a, D) miR-16-1 in all CLL. r=Spearman's rho correlation coefficient. 
 
Moreover, same inverse correlations were observed between the levels of TP53 and miR-
15a and miR-16-1 also in CLL cases with no chromosomal abnormalities (rs= -0.806, 
p<0.0001, Figure 6C,  and rs= -0.704, p<0.0001, Figure 6D; respectively). These 
observations supported a model in which TP53 mRNA levels in CLL are determined by 
levels of miR-15a and miR-16-1. 
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Relationship between TP53 and TERT levels 
Having established that deletion of miR-15a and miR-16-1 at 13q14 is likely to account for 
the high TP53 mRNA levels observed in CLL samples without TP53 deletion/mutation, we 
next sought to explain the reduced expression of telomerase in 13q14 patients. We have 
previously shown that 13q14del CLL cases expressed lower levels of TERT than CLL cases 
with other chromosomal abnormalities (Rampazzo et al, 2012). TP53 regulates a large array 
of genes, which mediate tumor-suppressive effects, such as inhibition of cell-cycle 
progression and induction of apoptosis. TP53 is also a very well-known down-regulator of 
TERT (Kanaya et al, 2000; Xu et al, 2000). 
 
To test this idea, both 13q14del and no FISH deletion CLL samples were analysed for the 
expression of TERT mRNA levels.  We found that 13q14del CLL expressed significantly 
lower levels of TERT than CLL with normal cytogenetic profile (55 [20-115] vs 73[46-198] 
copies/10
6
 copies GAPDH, p= 0.027; Figure 7A). 
 
Finally, we associated the TERT levels with TP53 mRNA levels and found that TERT 
mRNA levels negatively correlated with TP53 mRNA levels. Of interest, we found a 
negative correlation between TP53 and TERT levels only in the 13q14del CLL (rs= -0.359, 
p= 0.002, Figure 7B), but not in CLL without chromosomal abnormalities (rs= 0.111, p= 
0.484, Figure 7C).  
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Figure 7. A) Relative levels of TERT in CLL with no FISH abnormalities or with 13q14 deletion 
(13q14del). Boxes and whiskers represent 25-75th and 10-90th percentiles, respectively; median is 
the central line in each box. B) Relationship between TERT and TP53 levels in 13q14del CLL. C) 
Relationship between TERT and TP53 levels in CLL with no chromosomal abnormalities. 
r=Spearman's rho correlation coefficient. 
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Correlations with the percentage of 13q14 deletions detected by FISH 
Distribution of data we obtained was clearly variable among 13q14 deleted CLL patients. 
Some CLL cases showed remarkably high and some low levels of mRNA expressions.  We 
sought to clarify the quantitative variation in mRNA expression between individual cases 
due to different percentage of 13q14 deletions.  It has been shown that the percentage of 
deleted nuclei refines the prognosis of 13q14del CLL cases. The percentage of the 13414 
deletion within each case, was detected by fluorescence in situ hybridization (FISH) 
analysis. 
The different percentage of nuclei carrying the 13q14 deletion in fact explained the variable 
levels of miRNAs, TP53, and TERT observed within the 13q14del CLL group; indeed, the 
percentage of nuclei carrying the 13q14 deletion negatively correlated with both miR-15a 
rs= -0.324, p= 0.006, Figure 8A) and miR-16-1 (rs= -0.288, p= 0.016, Figure 8B) levels. 
Moreover, the percentage of nuclei carrying the 13q14 deletion positively correlated with 
TP53 levels (rs= 0.317, p= 0.004, Figure 8C) and negatively correlated with TERT levels 
(rs= -0.277, p= 0.007, Figure 8D). 
Taken all together, these data support the concept that there is a network among miR-
15a/miR-16-1, TP53 and TERT  within the 13q14del CLL (Figure 9A). 
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Figure 8. Relationship between percentage of 13q14 deleted nuclei and A) miR-15a, B) miR-16-1, 
C) TP53  and D) TERT levels. r=Spearman's rho correlation coefficient. 
 
 
Prognostic value of TERT and TP53 levels in CLL 
Kaplan-Mayer analysis showed that low TERT levels (below the median) are prognostic of 
better disease outcome, estimated as TTFT, in the entire cohort of CLL here studied  (Table 
1), and even in the subgroup of patients with 13q14del CLL (Figure 9B). 
Of interest, cases with high TP53 expression have a better prognosis in the subgroup of 
13q14del CLL ( Figure 9C), but not in the subgroup of CLL  with normal cytogenetics 
profile (Table 2). Within the 13q14del CLL, high TERT/low TP53 levels define the 
subgroup of cases with the worse prognosis, and multivariate analysis confirmed the 
independent value of TERT/TP53 profile in relation to IGVH mutational status (Table 3).     
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Figure 9. A) Proposed network between miR-15a/miR-16-1, TP53, and TERT expression. Down-
regulation of miR-15a/miR-16-1, due to 13q14 deletion, leads to increased of TP53 levels which, in 
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turn, down-regulate levels of TERT, the catalytic component of the telomerase complex. Treatment-
free survival [time from diagnosis to first treatment (TTFT)] curves in patients with 13q14del CLL 
according to B) TERT levels; C) TP53 levels; and D) in patients with different TERT/TP53 profiles. 
 
 
Table 1. Time and Hazard ratio of IGVH status, TERT levels and TP53 levels for their 
effects on disease progression in all CLL cohort 
 TTFT
x 
months  
(95% CI)
▪
 
p-value 
log-rank 
Hazard ratio 
(95% CI)
▪
 
HR 
p-value 
IGVH status  < 0.0001   
IGVH mutated 211 (107;221)  1  
IGVH unmutated 44 (18;157)  4.0 (2.1;7.4) < 0.0001 
TERT levels  0.008   
TERT low* 149 (107;-)  1  
TERT high* 82 (67;157)  2.2 (1.2;4.0) 0.009 
TP53 levels  0.123   
TP53 low* 109 (72;-)  1.7 (0.9;3.3) 0.127 
TP53 high* 157 (149;-)  1  
 
*TERT or TP53  low: TERT  or TP53  <= median; TERT or TP53  high: TERT or TP53  > median; 
xTTFT: time to first treatment; ▪CI: Confidence Interval 
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Table 2. Time and Hazard ratio of IGVH status, TERT levels and TP53 levels for their effects on 
disease progression in CLL with no chromosomal aberrations 
 TTFT
x 
months  
(95% CI)
▪
 
p-value 
log-rank 
Hazard ratio 
(95% CI)
▪
 
HR 
p-value 
IGVH status  0.007   
IGVH mutated 109 (86;-)  1  
IGVH unmutated 56 (14;68)  6.0 (1.4;25.4) 0.015 
TERT levels  0.047   
TERT low* 109 (86;-)  1  
TERT high* 72 (45;-)  2.9 (0.97;8.7) 0.057 
TP53 levels  0.969   
TP53 low* 109 (72;-)  1.0 (0.3;3.4) 0.973 
TP53 high* - (20;-)  1  
TERT&TP53 levels  0.590   
TERT high* & TP53 high* - (1;-)  1.0 (0.3;3.4) 0.966 
TERT low* & TP53 low* 109 (86;-)  0.5 (0.1;1.5) 0.197 
TERT high* & TP53 low* 72 (44;-)  1  
TERT low* & TP53 high* - (18;-)  0.4 (0.1;2.2) 0.321 
 
*TERT or TP53  low: TERT  or TP53  <= median; TERT or TP53  high: TERT or TP53  > median; 
xTTFT: time to first treatment; ▪CI: Confidence Interval 
 
 
 
 
 
 
 
 
 
 
29 
 
Table 3.  Time and Hazard ratio of IGVH status, TERT levels and TP53 levels for their effects on 
disease progression in CLL with 13q14 deletion 
 
 
TTFT
x
 
months  
(95% CI)
▪
 
p-value 
log-rank 
Hazard ratio 
(95% CI)
▪
 
HR 
p-value 
IGVH status  < 0.0001   
IGVH mutated 211 (110;-)  1  
IGVH unmutated 32 (6;157)  4.1 (1.9;8.6) 0.0003 
TERT levels  0.026   
TERT low* 211 (104;-)  1  
TERT high* 84 (53;157)  2.2 (1.1;4.7) 0.030 
TP53 levels  0.038   
TP53 low* - (32;-)  2.3 (1.02;5.5) 0.041 
TP53 high* 157 (149;-)  1  
TERT&TP53 levels  0.012   
TERT high* & TP53 high* 157 (153;-)  0.2 (0.06;0.8) 0.025 
TERT low* & TP53 low* - (96;-)  0.3 (0.07;1.0) 0.047 
TERT high* & TP53 low* 32 (5;-)  1  
TERT low* & TP53 high* 221 (104;-)  0.3 (0.1;0.8) 0.013 
TERT, TP53 levels & IGVH status  < 0.0001   
Other; IGVH unmutated 157 (1;157)  0.3 (0.1;0.7) 0.006 
Other; IGVH mutated 221 (104;-)  0.1 (0.03;0.4) 0.0004 
TERT high* & TP53 low*; IGVH 
unmutated 12 (1;32)  1  
TERT low* & TP53 high*; IGVH 
mutated - (25;-)  0.4 (0.1;1.0) 0.040 
 
*TERT or TP53  low: TERT  or TP53  <= median; TERT or TP53  high: TERT or TP53  > median; 
xTTFT: time to first treatment; ▪CI: Confidence Interval 
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5. DISCUSSION 
 
In CLL, molecular mechanisms resulting in disease development are still not clearly 
understood; therefore, the identification of factors that could predict the clinical course of 
CLL represents a crucial objective to manage this malignancy. The discovery that miR-
15a/16-1 is a main target of 13q14 deletion in CLL was the initial step in uncovering of one 
critical mechanism in CLL pathogenesis. As the miR-15a/16-1 cluster targets not only 
BCL2, but also TP53, (Fabbri et al, 2011) the  intact  TP53 tumor suppressor pathway, due 
to the  loss of miR-15a/16-1 expression, may  explain the more indolent form of disease 
described in the 13q14del CLL.5 Nonetheless, also these patients present variability in their 
disease outcome. Since TP53 is an important negative regulator of TERT, (Kanaya et al, 
2000; Xu et al 2000) a prognostic marker of CLL outcome, we investigate the role of miR-
15a/miR16-1 and TP53 in relation  to TERT levels and  CLL outcome.  
As expected, we found  that levels of both miR-15a and miR-16-1 were lower in 13q14del 
CLL than in CLL with no chromosomal abnormalities, while TP53 levels were higher in 
13qdel CLL. Moreover, levels of  miRNAs and TP53  in 13q14del CLL were correlated 
with percentages of deleted nuclei. It should be noted that miRNAs expression varied also 
in CLL with no chromosomal aberrations; therefore, other mechanisms than deletion of 
miRNA cluster in the 13q14 region, should contribute to regulate their expression. It has 
been recently demonstrated that miR-15a/miR16-1 and TP53 are engaged in a feedback 
circuitry loop in CLL: increased levels of miR-15a/miR16-1 target and down-regulate TP53 
expression, while TP53 binds to its specific binding sites on chromosome 13 and up-
regulates the expression of  miR-15a/miR-16-1 in CLL with normal cytogenetic profile 
(Fabbri et al, 2011). As the expression on of TP53 is influenced by many factors in CLL 
pathology (Wang et al, 2013) this variability may influence miRNA levels which in turn 
down-regulate TP53 expression. 
An interesting and intriguing result of our study is that levels of TP53 inversely correlated 
with TERT levels only in 13q14del CLL. At transcriptional level, more than 20 
transcription factor-binding sites acting as activators or repressors have been identified 
within the TERT promoter (Dolcetti et al, 2012). Cooperation of MYC and SP1 is required 
for the full activation of the TERT promoter, while TP53 protein, through its interaction 
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with SP1, down-regulates TERT (Kanaya et al, 2000; Xu et al 2000). It is possible that 
TP53 acts as a main driver in TERT regulation in 13q14del CLL, while in CLL with no or 
other chromosomal aberrations TERT is regulated by many other factors.  
Notably, we found that  TP53 had prognostic value only on 13q14del CLL. This result, 
together with the finding that a  negative correlation between TP53 and TERT levels can be 
observed only in 13q14sel CLL and not in CLL with normal cytogenetic profile, emphasizes 
the existence of a network between miR-15a/miR-16-1, TP53 and TERT within the 
13q14del CLL. It has recently been advanced by some studies (Dal Bo et al, 2011; 
Hernandez et al, 2009; Rodriguez et al, 2012) that CLL with a high percentage of 13q 
deletion  tend to have a worse prognosis. The deletion of miR-15a and miR-16-1 and the 
consequent lack of inhibition of the antiapoptotic BCL2 gene may partially support this 
trend. Nonetheless, miR-15a and miR-16-1 also target the tumor suppressor gene TP53. 
Hence, the loss of the miR-15a/miR-16-1 cluster due to 13q14 deletion not only shifts the 
balance toward higher levels of antiapoptotic proteins, but also toward higher levels of 
tumor suppressor entities, such as TP53. With a cut-off of 80% of 13q14 deleted nuclei 
(Hernandez et al, 2009; Rodriguez et al, 2012) we did not find any significant differences 
in disease outcome (chi-quadrate 2.307, Log Rank=0.129). This supports the concept that, 
rather than the percentage of deletion per se, the effects of the deletion influence the disease 
outcome.  
In conclusion, all together these findings indicate that in 13q14del CLL the miR15/16-16-1 
cluster and TP53 axis may be an important pathway, which regulates TERT expression and 
its activity, thus influencing the disease outcome. The regulation of TERT driven by miR-
15a/16-1 and TP53 may explain why TERT levels are low in the CLL patients carrying 
13q14 deletions, and miR-15a and miR-16-1 may become useful biomarkers or therapeutic 
targets for CLL cases with 13q14 deletion. Finally, the analysis of TERT/TP53 profile may 
be  particularly useful in refining the prognosis of patients with 13q14del CLL. 
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CHAPTER TWO 
Targeting MEK/ERK pathway as a novel therapeutic prospective in CLL 
 
 
1. INTRODUCTION 
 
B cell receptor complex 
Both immature and mature B cells recognize and generate signals for B cell responses to 
antigens through multi-protein complexes termed B cell receptor (BCR). The BCR is 
composed of the ligand-recognizing Ig heavy and light chains in noncovalent association 
with Igα (CD79a) and Igβ (CD79b) transmembrane proteins. Igα and Igβ are associated as 
disulfide-linked heterodimers and mediate the signal transduction function of the BCR. 
Antigen-mediated aggregation of BCR complexes is required to trigger and sustain the 
signaling processes necessary for generating a signal of sufficient strength and duration to 
elicit responses by immature and mature B cells. The BCR triggers an intracellular signaling 
cascade that requires immunoregulatory tyrosine activation motifs (ITAMs) present on the 
cytoplasmic domains of Igα and Igβ (Coggeshall et al, 2000; Wienands et al, 2000). 
Tyrosine residues on these motifs become phosphorylated, and serve as hubs for the 
recruitment of additional kinases and adaptor proteins, and subsequent activation of multiple 
signaling cascades (Hsueh et al, 2000).  
 
Figure 10. B cell receptor (BCR) components signaling (Woyach et al, 2012). The BCR consists of 
the antigen-binding heavy chains IgH and light chains IgL that are coupled to the Ig-α (CD79A) 
and Ig-β (CD79B) signaling subunits.  
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BCR signaling in CLL 
Analysis of CLL cells isolated from the blood and lymph nodes provided direct evidence for 
antigen-dependent signaling through the BCR in (Herishanu et al, 2011). BCR signaling is 
likely a key driver of CLL proliferation since in vitro BCR activation supports CLL cell 
survival and proliferation (Longo et al, 2008; Paterson et al, 2012). Strong cellular 
response to BCR activation correlates with a more aggressive disease course of CLL (Le 
Roy et al, 2012; Gobessi et al, 2007). Consistent with these in vitro data, the degree of 
BCR activation in CLL cells in vivo correlates with increased tumor proliferation and 
shorter time to progression (Herishanu et al, 2011).  
 
Figure 11. Antigen encounter and BCR clustering promotes tyrosine phosphorylation of the ITAMs 
SYK, triggering the activation of a BTK, PI3Kδ, and MAP kinase, leading to cell survival and 
proliferation (Bannish et al. 2001). 
 
Antigen encounter and BCR clustering promotes tyrosine phosphorylation of the ITAMs by 
Src-family kinases such as LYN, FYN, and BLK. Phosphorylated ITAMs then recruit 
spleen tyrosine kinase (SYK) through interactions with its SH2 domains. SYK activation 
triggers activation of a signaling cascade that engages Bruton's tyrosine kinase (BTK), 
phosphoinositide 3-kinases (PI3Ks; including PI3Kδ), nuclear factor (NF)-κB, PI3K, 
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nuclear factor of activated T cells (NF-AT), mitogen-activated protein (MAP) kinase, and 
RAS signaling pathways, leading to cell survival and proliferation (Bannish et al. 2001). 
 
MAPKs pathway 
The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most conserved 
signaling pathways amongst eukaryotes, and controls basic cellular events like proliferation, 
differentiation, survival and apoptosis. In this pathway, different protein kinases trigger a 
cascade of signals by sequential phosphorylation events in a hierarchical way. One of the 
best characterized elements of the MAPK pathway are MEK1/2 and ERK1/2.  
MEK1/2 
MEK1 and MEK2 are related protein kinases that participate in the RAF-MEK-ERK signal 
transduction cascade. This cascade participates in the regulation of a large variety of 
processes including apoptosis, cell cycle progression, cell migration, differentiation, 
metabolism, and proliferation. Activated RAF directly phosphorylates and activates 
MEK1/2 at two serine residues (Ser217 and Ser221) that are localized in their activation 
loop. Two MEK homologues, MEK1 and MEK2 are ubiquitously expressed in mammals. 
Both of these MEKs sequentially phosphorylate ERK1 and ERK2 at two sites - Tyr185 
followed by Thr183 (Sebolt-Leopold et al, 2004).  
In vitro expression of constitutively active forms of MEK has been shown to result in 
transformation, giving rise to highly tumorigenic cell lines (Mansour et al, 1994). 
Similarly, MEK has been implicated in the development of a broad range of human tumours 
(Hoshino et al, 1999). Studies carried out in a large number of tumor types have indicated 
the importance of MEK, which activates ERK, in driving their proliferation and, often, 
progression. 
 
ERK1/2 
MEK1/2 activation induces the downstream phosphorylation of ERK1/2 at level of 
Threonine 202 and Tyrosine 204. ERK is the most downstream protein of MAPK pathway 
that acts directly on cellular substrates, and its phosphorylation is associated with different 
functions, including cell cycle regulation, but also is necessary for regulating lymphocyte 
activation status and responsiveness to antigens (Packham et al, 2014). Several reports 
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suggest that ERK activity can be modulated in terms of duration and magnitude (Ebisuya et 
al, 2005). In physiological conditions, ERK signalling is tightly controlled by feedback 
loops at multiple levels, which are essential for maintaining regulated cell growth and 
homeostasis. Activated ERK phosphorylates a number of substrates, including other kinases 
and transcription factors, which execute programmes related to cell cycle progression, 
differentiation, protein translation and evasion from cell death (Samatar et al, 2014). 
 
 
Figure 12. Schematic representation of MAPK signaling pathway and the prototypic MEK1/2 and 
ERK1/2 interaction. 
 
MEK1/2 inhibitors 
MEK kinases have been mostly studied as possible therapeutic targets in cancers and MEK 
inhibitors are under evaluation for the treatment of solid tumors (Fremin & Meloche, 
2010). The rationale for targeting MEK1/2 is that it has a central role in the MAPK pathway 
and in transducing proliferative stimuli in a broad spectrum of human cancer cells. 
Oncogenic mutations in RAS or B-RAF are responsible for a large proportion of human 
cancers and causes constitutive MEK kinase activation. MEK1/2 inhibitors have also been 
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analyzed in several preclinical studies for the treatment of haematological malignancies 
(Steelman et al, 2011). 
The high degree of sequence homology between MEK1 and MEK2 makes it likely that a 
small-molecule MEK inhibitor would target both homologues. The development of 
pharmacological inhibitors of MEK initiated with the discovery of PD098059 (Dudley et al, 
1995). U0126, a MEK inhibitor shown to be more potent than PD98059, has been widely 
used for investigating the role of this pathway in cellular events (Favata et al, 1998). The 
first MEK inhibitor reported to inhibit tumor growth in vivo was PD184352 (Sebolt-Leopold 
et al, 1999). It was shown to significantly inhibit the growth of colon carcinomas in animal 
models (Sebolt-Leopold et al, 1999). Based on a promising preclinical profile that 
encompassed effects on proliferation, survival, invasion and secretion of pro-angiogenic 
growth factors, this agent was moved  into the clinical setting into clinical oncology (Allen 
et al, 2003). 
In addition, anticancer activity of a novel MEK1/2 inhibitor, Trametinib has been 
demonstrated for a broad spectrum of human tumor. Trametinib is a reversible and highly 
selective allosteric inhibitor of MEK1 and MEK2 with anticancer activity against metastatic 
melanoma. Trametinib activity has been evaluated in the treatment of variety of cancers, and 
is currently approved as a monotherapy for subjects with metastatic melanoma with BRAF 
V600E/K mutation (Rissmann et al, 2015). In xenografted tumor models, trametinib 
showed sustained inhibition of ERK phosphorylation, suppression of Ki67, and growth 
inhibition in tumor lines with mutant BRAF or RAS (Yamaguchi et al, 2011). Trametinib 
also decreases cell proliferation, causes G1 cell cycle arrest, and induces apoptosis 
(Gilmartin et al, 2011).  
 
Small-molecule inhibitors of BCR signaling 
Small molecule inhibitors can target several kinases in the BCR pathway. Most advanced in 
their clinical development are inhibitors of BTK, PI3K, and SYK inhibitors. Preclinical in 
vitro and in vivo studies identified these kinases as promising targets for the treatment of 
CLL and other B-cell malignancies (Wiestner et al, 2012), and their inhibition effectively 
interrupts BCR signaling, leading to reduced activation and proliferation of tumor cells 
(Herman et al, 2010).  
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Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that is essential for BCR 
signaling and couples BCR induced calcium release to activation of the NF-κB pathway and 
cellular proliferation. (Honigberg et al, 2010). Ibrutinib (PCI-32765) is an orally 
bioavailable BTK inhibitor that irreversibly inactivates the kinase by covalently binding to a 
cysteine residue Cys481 (Honigberg et al, 2010; Pan et al, 2007). It has been shown that, 
Ibrutinib significantly decreases the CLL cell survival and proliferation, cell migration, and 
production of the chemokines (Ponader et al, 2012; Rooij et al, 2012). In the TCL1 mouse 
model of CLL, BTK inhibition leads to a profound inhibition of CLL progression and 
survival (Ponader et al, 2012). Several combination studies of Ibrutinib with frontline 
settings are currently ongoing.  
 
B Cell Anergy 
Anergy was described as a state of lethargy of B lymphocytes, that persist in the periphery 
but are unresponsive to their antigen. The molecular mechanisms underlying anergic B cells 
lack of responsiveness reside both in BCR proximal and distal signaling (O'Neill et al, 
2011).  
 
Figure 13. Variable BCR signaling responses influence clinical outcome via differential effects on 
anergy and positive signaling. Antigen engagement appears to be ongoing in all CLL with anergy 
being the predominant outcome. Thus, markers of anergy (sIgM downmodulation, raised basal ERK 
phosphorylation and NFAT) are more prominent in good prognosis subsets.  
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The chronic basal activation of anergic B lymphocytes, results in constitutive 
phosphorylation of ERK1/2 kinases and nuclear translocation of nuclear factor of activated 
T cells c1 (NF.ATc1) (Dolmetsch et al, 1997; Healy et al, 1997) and constant BCR 
engagement induces sustained low level intracellular calcium levels (Benschop et al, 2001; 
Healy et al, 1997). 
In addition, anergic biochemical program is not permanent, but it requires continuous 
antigen binding, since many features of B cell anergy can be rapidly reversed by the 
termination of self antigen–induced signalling. These include recovery of BCR-mediated 
intracellular calcium mobilization, loss of ERK1/2 phosphorylation and expression of 
activation markers (Gauld et al, 2005). Anergic B cells display significantly weaker 
proliferation, impaired differentiation, and poorer Ab production after BCR stimulation 
(Isnardi et al, 2010).  
It has been suggested that, in at least a proportion of patients, CLL cells might represent 
anergic B cells abnormally expanded (Muzio et al, 2008; Mockridge et al, 2007). 
Previously it has been reported that in approximately one-half of CLL cases, leukemic cells 
constitutively express phosphorylated ERK1/2 and MEK1/2 together with activated NF-
ATc1 transcription factor (Apollonio et al, 2013). In addition, anergic CLL cells are 
characterized by cellular unresponsiveness to surface Ig ligation in terms of 
phosphotyrosine induction (Muzio et al, 2008).   
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2. AIMS 
 
Several evidences indicate that B cell receptor (BCR) stimulation is involved in the 
natural history of disease of CLL. Relevant proportion of CLL patients show 
biochemical and functional features of anergic B cells, characterized by the lack of 
signalling capacity and constitutive activation of ERK1/2 and NF-ATc1. Anergy is 
the mechanisms that the immune system adopts to silence autoreactive B 
lymphocytes. Therefore, it is reasonable to suggest that reversing the anergic state of 
these CLL might be beneficial in terms of clinical responses. Recently, several small 
molecule inhibitors of MEK1/2 have been developed. During the second part of my 
PhD studies, we tested the effect of the MEK inhibitor Trametinib in CLL, both in 
vitro and in vivo. In addition, Trametinib was combined with the BTK inhibitor, 
Ibrutinib to assess if blocking of BCR signalling would increase its cytotoxic effect.  
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3. MATERIALS AND METHODS 
 
Tissue samples and cell purification  
Leukemic lymphocytes were obtained from peripheral blood of CLL patients, diagnosed 
according to National Cancer Institute Working Group (NCIWG) guidelines (Hallek et al, 
2008). All patients were either untreated or off therapy for at least 6 months before the 
beginning of the study. The following parameters were analyzed for each patient: age, sex, 
disease stage at diagnosis according to Binet or modified Rai (Rai et al, 1975) criteria, 
CD38 expression, IGHV gene mutational status (Hamblin et al, 1999), ZAP70 expression 
(Wiestner et al, 2003), characterization of disease as progressive or stable as defined by the 
NCIWG and survival time. Leukemic cells were purified immediately after blood 
withdrawal using a B-lymphocyte enrichment kit (RosetteSep, StemCell Technologies). 
Purity of all preparations was always more than 99%, and the cells coexpressed CD19 and 
CD5 on their cell surfaces as checked by flow cytometry (FC500; Beckman Coulter); 
preparations were virtually devoid of natural killer (NK) cells, T lymphocytes, and 
monocytes.  
CD19+ B lymphocytes were purified from PB of healthy donors (buffy coat) by negative 
selection with the use of a B lymphocyte enrichment kit (RosetteSep; StemCell 
Technologies) following the manufacturer's instructions and further purified with the use of 
EasySep™ Human B Cell Enrichment Kit (Stem Cell Technologies). Purity of CD19+ 
lymphocytes was greater than 98%. All tissue samples were obtained with the approval of 
the institutional Ethics Committee of San Raffaele Scientific Institute. Informed consent 
was obtained according to the Declaration of Helsinki. 
 
Cell lines and Cell culture and inhibitors 
The stable cell lines JURKAT (T cell leukemia), DAUDI (Burkitt lymphoma), RPMI-8226 
(multiple myeloma), RIVA (diffuse large B cell lymphoma), THP1 (acute monocytic 
leukemia), Ly-3 (diffuse large B cell lymphoma)  and MEC1 (CLL) were obtained from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DsMZ, Germany).   
Purified primary leukemic cells were cultured in RPMI 1640 medium supplemented with 
10% fetal calf serum (FCS), 2 mM L-glutamine and 15 ug/mL gentamicin (complete RPMI; 
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Invitrogen), at the concentration of 5 x 10
6
 cells/mL in the presence or the absence of 
different stimuli or inhibitors as indicated. All cells lines were maintained at a density of 
2x10
5
 – 1x105 cells per mL in 25 cm2 filtered flasks. For in vitro studies Trametinib and 
Ibrutinib were purchased from Selleck Chemicals and for in vivo experiments were 
purchased from MedChem Express.  
 
Western blot analysis and antibodies 
Cells (10 million cells per sample) were pelleted, resuspended in cold lysis buffer (150 mM 
NaCl, 1% NP40, 50 mM Tris HCl, 1 mM EDTA, protease inhibitors, phosphatase 
inhibitors) and spin in microcentrifuge at 4°C for 20 minutes at 16 000g; lysate was 
recovered from supernatant. Whole protein extracts (30 μg) were resolved by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDSPAGE), and proteins from gel 
were electron-transferred onto nitrocellulose membranes and incubated with anti phospho-
ERK1/2, anti phopsho-MEK1/2, anti phopsho-PD1, anti TCL1 (Cell Signaling 
Technology), anti ERK1/2, anti BTK (from Santa Cruz). antibodies were diluted in a 
solution of PBS+0,1% Tween (PBST) containing 5% of non fat dry milk according to 
manufacturers’ instructions. Specific secondary antibodies HRP-conjugated were used for 
the detection of corresponding primary antibodies used for Western blot analysis: goat anti-
rabbit Ig, goat anti mouse Ig (Sigma). Immunoreactivity was revealed by incubation with 
secondary antibodies conjugated with Horseradish Peroxidise (HRP). Densitometric 
analysis of ERK-specific bands was performed using ImageQuant Software (GE 
Healthcare). The values of individual patients were calculated as percentage of the positive 
control (MEC1 cell line) and determined as the ratio of the OD of phospho-ERK and OD of 
total ERK. 
 
 
 
Analysis of cell viability and apoptosis 
After each different treatment at indicated doses and time points, the percentage of viable 
cells was determined using the CellTiter-Glo Luminescent Cell Viability Assay kit, 
according to the manufacturer's instructions (Promega). All measurements were performed 
in duplicate and the viability of treated cells was normalized to the relative untreated 
control.  
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Induction of apoptosis was evaluated by double staining with FITC (fuorescein 
isothiocyanate)-conjugated Annexin V and PI (propidium iodide), using the Annexin V- 
FITC Apoptosis Detection Kit (eBioscence), according to the manifacturer’s instructions. 
Samples were analyzed on a FC500 flow cytometer (Beckman Coulter). 
 
Nucleofection of MEC1 cell line 
With the use of the Nucleofector system (Amaxa Biosystems), specific siRNA’s were 
introduced into MEC1 cells (6 × 10
6
 cells) after resuspension in 100 μL of Cell Line 
Nucleofector Solution L. Then cells were mixed with 1 μg of the siMek1, siMek2 or 
scramble siRNA (Origene) used as a negative control. Nucleofections were done with the 
use of the Amaxa Nucleofector device with the C-05 program. Transfection efficiency was 
assessed by mRNA quantifications. Nucleofected MEC1 cells were collected and processed 
for quantification analysis at 24 and 48 hours after nucleofection. 
 
RNA extraction and real-time polymerase chain reaction 
Total RNA was extracted from cells with the use of ReliaPrep™ RNA Cell Miniprep 
System (Promega) according to the manufacturer's protocol. Quantification of Mek1 and 
Mek2 mRNA levels were achieved by real-time polymerase chain reaction (PCR) using Fast 
SYBR® Green Master Mix (ThermoFisher Scientific) and ABI-7500 (Applied Biosystems) 
according to manufacturer's instruction. Briefly, 500 ng of total RNA was reverse-
transcribed (RT), subsequently RT product with specific primers was used as template for 
real-time PCR. All real-time experiments were performed in triplicate. Data were analyzed 
with the SDS2 software (Applied Biosystems) following the manufacturer-suggested 
comparative method. Data were normalized on the expression of Actin and expressed either 
as fold change relative to control (2−ΔCt). 
 
Cell synchronization 
MEC1 cells were synchronized by the addition of 2mM thymidine (Sigma-Aldrich) for 18 
hours, washed, and resuspended in complete RPMI, cultured for an additional 9 hours, and 
treated a second time with 2mM thymidine for an additional 12 hours. After the second 
incubation in thymidine, cells were washed twice in PBS to release from thymidine block 
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and resuspended in complete RPMI. Cells were analyzed for cell-cycle distribution at the 
time of release and  6 and 24 hours after the release. 
 
Cell-cycle analysis 
Transduced MEC1 cells were washed in PBS, resuspended in DNA staining buffer (PBS, 
1% NP-40, RNAse and 50 μg/mL propidium iodide), incubated for 10 minutes at room 
temperature and analyzed for DNA content on a FC500 cytometer (Beckman Coulter). Data 
were analyzed with CXP analysis software (Beckman Coulter). Cell doublets and debris 
were excluded from further analysis by gating individual cells in peak area versus peak 
width plot. 
 
Purification, adoptive transfer and culture of TCL1 leukemias  
The TCL1 leukemia cells that were used in the adoptive transfer experiments which have 
been obtained from the Eμ-TCL1 transgenic mouse spleen, which had a C57BL/6N 
background. For this reason, the adoptive-transfer experiments with these leukemias were 
done in C57BL/6N recipients (8-week-old male mice; Charles River Laboratories). TCL1 
leukemia cells (splenic lymphocytes) used in the adoptive-transfer experiments, were not 
purified because they represented more than 80% of the CD5/CD19 positive mononuclear 
cell population isolated from the spleens of leukemic animals. The purity of the selected 
populations was evaluated by staining with anti-CD5 phycoerythrin (PE)-conjugated and 
anti-CD19 PE-Cyanine7 (PC7)-conjugated antibodies (Affymetrix, eBioscience), followed 
by flow cytometric analysis on a FC500 cytometer (Beckman Coulter). For adoptive 
transfer, 10×10
6
 TCL1 leukemia cells were resuspended in sterile 300 μL PBS, and injected 
intraperitoneally into the syngeneic recipients.  
 
Statistical analysis 
Student's paired or unpaired t-tests were used for statistical comparisons. Comparison of 
survival curves was performed with the use of the log-rank test. Analyses were performed 
using GraphPad Prism 4 software (GraphPad Software, San Diego, CA, USA). A P-value 
<0.05 was considered as statistically significant. 
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4. RESULTS 
 
Investigating the MEK/ERK inhibitor Trametinib in leukemia and lymphoma cell 
lines 
Considering that, in a proportion of cases, CLL is a disease characterized by anergic B cell, 
showing constitutive phosphorylation of ERK, we sought to investigate whether the 
MEK1/2 inhibitor Trametinib could be effective in CLL cells in vitro and in vivo. To this 
purpose, we initially planned to study the effect of Trametinib in terms of growth inhibition 
and cytotoxic effect on stable cell lines.  
In order to determine the effective Trametinib concentration, experiments were performed 
by challenging exponentially growing CLL cell line MEC1 with a serial dilution of drug 
concentration and estimating growth inhibition between the treated and untreated condition. 
To identify a dose range, MEC1 cells were treated with Trametinib for 72 hours in cell 
culture. A concentration dependent decrease in viability was observed in our in vitro 
working conditions and we determined the effective Trametinib concentrations as 3μM 
(Figure14, left panel).  
 
Figure 14. Left panel: Viability of MEC1 cells after exposure to increasing concentration of 
Trametinib for 72 hours. Right panel: Western blotting analysis for phosphorylated ERK (pERK) in 
MEC1 cells after exposure to increasing concentration of Trametinib for 1 hour.  
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Figure 15. Left panel: Time course analysis of Trametinib. Viability of human CLL cell line, 
MEC1, treated with 3uM of Trametinib for 24, 48 and 72 hours in vitro. Right panel: Western 
blotting analysis for phosphorylated ERK in MEC1 cells after exposure to 3uM of Trametinib for 72 
hours.  
 
We then checked the ERK phosphorylation status in MEC1 cell line and found that ERK is 
constitutively active. To study whether Trametinib is able to decrease ERK phosphorylarion 
in vitro, we cultured MEC1 cells with Trametinib at different concentrations up to 3μM for 
1 hour and studied ERK phosphorylation status by western blot analysis. We observed that, 
starting from 0.1uM, Trametinib was able to decrease ERK phosphorylation in vitro (Figure 
15).  
To further validate the Trametinib effect in vitro, we employed a panel of six cell lines 
consisting of various leukemia (PCL12, THP1 and Jurkat), lymphoma (Ly3, Riva and 
Daudi) and multiple myeloma lines (RPMI-8226).   
We initially profiled their ERK phosphorylation status and found that all lines expressed 
constitutively phosphorylated [pERK(+),] (Figure 16). We then analyzed the proliferative 
response after 72 hour of culture with 3μM of Trametinib. At this concentration, Trametinib 
was able to reduce cell viability in all cell lines tested in our in vitro assay (Figure 3). In 
addition, the cells were treated in the same conditions with 3μM of Trametinib for 1 hour, 
and were then lysed and subjected to Western blot analysis for cellular ERK status. A 
decrease in ERK phosphorylation was observed in all cell lines we have tested.  
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Figure 16. Left: Inhibition of ERK phosphorylarion in vitro in various human leukemia and 
lymphoma cell lines. Cell were incubated with 3uM of Trametinib for 24 hour and then lysed for 
western blot analysis.  Right: Growth of different human cell lines incubated with 3uM of 
Trametinib for 72 hours. Cell lines: MEC1 and PCL12 (CLL Leukemia), THP1 (Acute Monocytic 
Leukemia), Ly-3 (Activated B-cell Diffuse Large B-cell Lymphoma), Jurkat (T-cell Leukemia), 
RPMI-8226 (Multiple Myeloma), Daudi (Burkitt's lymphoma) and Riva (Activated B-cell Diffuse 
Large B-cell Lymphoma) cells.  
 
Transfection experiments with siMEK1 and siMEK2 
To further confirm that Mek1/2 is an appropriate therapeutic target in CLL, we evaluated 
the functional consequences of Mek1 and Mek2 knockdown in the CLL cell lines MEC1. 
As shown in Figure 17, both Mek1 and Mek2 were efficiently down-regulated by RNA 
interference, with an approximately 70–80% reduction in mRNA levels as compared to cells 
transfected with control siRNA.  
 
Figure 17. Efficient siRNA mediated knockdown of Mek1 and Mek2 in MEC1 cells. mRNA levels 
were measured by qRT-PCR, 24 and 48 hours after transfection. 
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We then evaluated the viability of the transfected cell lines after 48 hour and 72 hour of 
siRNA transfection as well as induction of apoptosis after 72 hour of siRNA transfection. 
Down-regulation of Mek1 or Mek2 associated with a reduction in the viability of MEC1 
cells up to 50 % (Figure 18). Silencing Mek2 was more effective compared to Mek1 with 
inhibition of (>15%) and no further enhancement of this effect was seen when both Mek1 
and Mek2 were simultaneously silenced (Figure 18). 
 
Figure 18.  Cells transfected with appropriate targeting or scrambled control siRNAs were 
harvested for 48 and 72 hours after transfection.  
 
Furthermore, induction of apoptosis was determined by Annexin V-FITC/propidium iodide 
staining, followed by flow cytometric analysis. Downregulation of Mek1 or Mek2 induced 
the apoptosis of MEC1 cells and silencing Mek2 was more effective compared to Mek1 
(Figure 19).  
 
 
Figure 19. Induction of apoptosis. Annexin V binding was carried out with the Annexin V-FITC 
Detection Kit. The percentage values refer to live (annexin V
 
and
 
PI negative) cells present in the 
rectanguilar gate in each dot plotcells. 
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Relationship between ERK and MEK activation in human primary CLL cells 
Anergy has been described as a state of lethargy of B lymphocytes, that persist in the 
periphery and are unresponsive to antigenic stimulation. The molecular mechanisms 
underlying anergic B cells lack of responsiveness in BCR signaling in CLL is associated 
also with constitutive activation of ERK. These feature is considered a molecular signature 
of in vivo cellular anergization in patients with CLL (Mockridge et al, 2007; Muzio et al, 
2008; Apollonio et al 2013). 
 
 
Figure 20. MEK and ERK phosphorylation status in purified primary (fresh) CLL cells and healthy 
donors (normal)  CD19+ B cells. In all immunoblot analyses, MEC1 cell line were loaded together 
as positive control. 
 
To determine whether ERK is activated in human primary CLL cells, we examined the 
activity of MAPK pathway by western blot. The increase in MAPK activity was confirmed 
by immunoblot analysis using phospho-specific ERK1/2 and MEK1/2 antibody in 22 CLL 
samples and in 4 normal B cells obtained from healthy donors (buffy coat). We observed 
significant MEK and ERK phosphorylation activity in 12 out of 22 (54%) CLL samples  
analyzed (Figure 20).  ERK phosphorylation was considered positive when the cases where 
higher than 10% of the value measured in the MEC1 cells. Normal B cells purified by 
immunomagnetic methods from buffy coats of healthy donors, were also heterogeneous in 
terms of MAPK activity.   
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Figure 21. Correlation between MEK and ERK phosphorylation status in CLL cells. ERK1/2 
constitutive phosphorylation significantly correlated with MEK1/2 constitutive activation. 
 
 
In addition to ERK activation in CLL, we also examined the phosphorylation of MEK1/2 
using phospho-specific MEK antibody and determined whether the activation of ERK is 
accompanied by the activation of MEK. Activation of MEK in CLL cells was detected in 13 
of the 23 cases analyzed (59%) (Figure 20).  
ERK activation was positively associated with MEK activation, and this relationship was 
statistically significant (Figure 21, P = 0.003). 
 
Impact of ERK inhibition on human primary CLL cells: relationship with ERK 
phosphorylation 
To verify whether the inhibition of MEK might affect CLL cell survival in vitro, we treated 
freshly purified CLL cells with 3uM of Trametinib. By AnnexinV/PI staining analysis, we 
found that the use of Trametinib induced a decrease in cell viability and an induction of 
apoptosis in primary CLL cells from patients (Figure 22). We observed a significant 
reduction in viability in 18 CLL patients, when cultured with 3uM Trametinib (Figure 9), 
though at variable levels.  
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Figure 22. Freshly purified primary CLL cells were treated for 48 hours with 3uM of Trametinib 
and induction of apaoptosis was analyzed by AnnexiV and PI staining. 
 
Interestingly, we observed that MEK/ERK pathway activity (the anergic status of the CLL 
cells) was associated with the relative sensitivity to Trametinib in CLL cells in vitro. In 
detail, CLL samples that had constitutive ERK phosphorylation (9 pERK(+) samples) had a 
mean percentage of survival of 55.6% ± 6.9  compared with 83.8% ± 4.5  survival of the 9 
pERK(-) cases (Figure 23, P = 0.003).  
 
             
Figure 23. ERK pathway activity (the anergic status of the CLL cells) is a predictive marker for the 
relative sensitivity to Trametinib in CLL. 
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Figure 24. Representative plots showing the induction of apoptosis in primary pERK(-) and 
pERK(+) CLL cells. Annexin V binding was carried out with the Annexin V-FITC Detection Kit. 
The percentage values refer to live (annexin V
 
and
 
PI negative) cells present in the rectanguilar 
gate in each dot plot. 
 
In addition to viability experiments, ERK phosphorylation was examined after incubating 
the primary CLL cells with increased concentration of Trametinib. Treatment of the CLL 
with the Trametinib greatly reduced the phosphorylation levels of ERK, suggesting efficient 
and specific inhibition of the MEK/ERK pathway in leukemic cell. Trametinib was able to 
inhibit constitutive ERK1/2 phosphorylation in pERK(+) CLL samples, starting from low 
concentrations (Figure 25). 
 
Figure 25.  The levels of ERK1/2 inhibition in CLL cells treated for 1 hour with increasing 
concentration of Trametinib in vitro. 
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Furthermore, to verify potential differences among patients on the basis of ERK1/2 
phosphorylation levels, we have correlated the Trametinib mediated reduction in viability to 
the levels of ERK phosphorylarion in 9 CLL cases. We found significant positive 
correlation between the ERK1/2 phosphorylation levels of CLL cell (calculated by western 
analysis) and the Trametinib mediated reduction in viability (p = 0.0423).  CLL cases with 
the highest relative ERK phosphorylation level were the ones that were more sensitive to 
Tranetinib treatment (Figure 26).  
 
 
Figure 26.  Correlation between ERK1/2 phosphorylation levels of CLL cell and Trametinib 
mediated reduction in viability.   
 
Conversely, we did not observe any significant associations between the IGHV mutational 
status, CD38 positivity or progression status and Trametinib effect in our CLL cohort. 
 
MEK inhibition in purified normal B cells 
Normal B cells, isolated from 4 buffy coats (Figure 14) obtained from healthy donors were 
cultured with 3uM of Trametinib for 48 hours. We observed that Trametinib is able also to 
decrease the viability of purified CD19+ B cells (31%) though to a lesser extent as 
compared to CLL cells (45%) (Figure 28).     
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Figure 27. Representative plots showing the purity of the CD19+ normal B cells, isolated from the 
buffy coat of healthy donors.  
 
                            
 
Figure 28. Isolated normal B cells were treated for 48 hours with 3uM of Trametinib and induction 
of apaoptosis was analyzed by AnnexinV and PI staining. 
 
Combined ERK and BTK inhibition in vitro 
After demonstrating the efficacy of Trametinib as single agent, we further evaluated its 
effect in combination with the BTK inhibitor Ibrutinib on leukemia cell lines and primary 
CLL lymphocytes. The efficacy was assessed in terms of cytotoxicity and induction of 
apoptosis. Changes in protein expression were assessed by western blotting analysis. We 
first exposed CLL cell lines MEC1 and PCL12 to 3μM Trametinib, 1μM Ibrutinib and to the 
combination of both drugs in vitro, for 72 hours (Figure 29).  
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Figure 29. Impact of combined ERK and BTK inhibition in cells lines 
 
 
The same sets of experimetns were also repeated on human primary CLL cells. The capacity 
to potentiate induction of apoptosis was assessed by annexin-V staining. As expected, 
Ibrutinib alone was able to reduce viability of CLL cells but no synergistic effects was 
apparent between Trametinib and Ibrutinib when compared to either drug alone (Figure 30). 
 
 
Figure 30. Combined ERK and BTK inhibition in human CLL cells: effects on viability measured as 
Annexin/PI negative cells in culture in the presence of Trametinib 3uM alone, Ibrutinib 1uM alone 
and the combination of both drugs 
 
Interestingly, as for Trametinib, also Ibrutinib was less effective in decreasing the viability 
of pERK(-) CLL cells when compared to pERK(+) cells (Figure 31). 
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Figure 31. Trametinib and Ibrutinib dose response in pERK(+) and pERK(-) CLL cells. 
 
Cell cycle analysis  
To further clarify the role of Trametinib and Ibrutinib in regulating proliferation, we 
synchronized CLL MEC1 and PCL12 cell lines with thymidine for 48 hour and evaluated 
their cell cycle distribution in 24 hour after release from thymidine block. After release from 
thymidine block, MEC1 cells were treated with Trametinib 3μM, Ibrutinib 1μM or with 
combination of both Trametinib and Ibrutinib. Cells treated with Trametinib showed 
increased percentage of cells in G1 and reduced percentage of cells in S and G2 phase, 
indicating a block at G1 phase of the cell cycle (Figure 32). Cells treated with Ibrutinib also 
had reduced percentage of G1 but at a lesser extent compared to Trametinib. Again, no 
differences were seen when both Trametinib and Ibrutinib was used together.  
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Figure 32. Cells were synchronized with thymidine for 48 hour, treated with Trametinib 3 μM or 
Ibrutinib 1 μM, and analyzed for cell-cycle distribution by PI staining and flow cytometry 24 hours 
after release from thymidine block. Upper graph: Cell cycle analysis of MEC1 and PCL12 cell 
lines. Lower graph: Representative cell cycle analysis plots of cells in pre treatment, Thymidine 
block release and after 24 hour of treatment. 
 
In vivo activity of Trametinib in TCL1 transgenic mouse model of CLL 
Due to the similarity with human CLL, TCL1-transgenic mice are extensively used in the 
dissection of the pathogenic mechanisms leading to CLL.  
In order to study Trametinib effect in vivo, we started investigating whether TCL1 
leukemias express constitutively active ERK, as described for human CLL. We have 
isolated the splenocytes from leukemic TCL1-tg spleen, and observed significant 
phosphorylation of ERK in all investigated TCL1 mice we have analyzed (Figure 33, left). 
Then, TCL1 splenocytes, isolated from TCL1-tg spleen, were placed in culture with 
Trametinib alone or in combination with Ibrutinib to evaluate a possible cytotoxic effect. 
Trametinib effectively decreased the viability (59% ± 4.5) of four different TCL1 leukemias 
that we analyzed (Figure 33, right).   
                       
Figure 33. Left: ERK phosphorylation status in 2 representative saples of normal and TCL1-tg 
leukemic mice cells. Right: Isolated TCL1 cells from a representative animal were cultured in vitro 
to study the effect of the ERK and BTK inhibitors on viability 
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In addition to viability experiments, we checked if Trametinib was able to decrease the ERK 
phosphorylation of TCL1 cells in vitro. Freshly isolated splenocytes were cultures in vitro 
for 48 hours with MEK inhibitor. Similarly, to human anergic CLL cells, Trametinib was 
able to inhibit the ERK1/2 phosphorylation level in all TCL1 leukemias that we have 
analyzed (Figure 34).   
 
 
Figure 34. Western blot analysis of TCL1 cells cultured with MEK and BTK inhibitors for 1 hour to 
study the reduction in phosphorylation. 
 
We then checked if Trametinib is able to reduce ERK phosphorylation in vivo. To this 
purpose, 3 mg/kg of Trametinib was administered to mice by oral gavage, and ERK status 
was followed 6 hour and 24 hours post administration. Single Trametinib dose completely 
inhibited ERK phosphorylation in 6 hours and inhibition lasted for at least for 24 hours in 
TCL1-tg mouse in vivo (Figure 35).  
 
Figure 35.  Western blot analysis of ERK phosphrylation status of mice treated with Trametinib in 
vivo for 6 hours and 24 hours. 
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To study a possible effect on survival by Trametinib in vivo, we used the TCL1 transgenic 
mouse spleen cells for adoptive transfer experiments. TCL1 leukemia cells represent more 
than 80% of the CD5/CD19 positive mononuclear cell population of the spleens of leukemic 
animals (Figure 36). For adoptive transfer, 10×10
6
 TCL1 leukemia cells were resuspended 
in sterile 300 μL PBS, and injected intraperitoneally into syngeneic recipients.  
 
Figure 36 The purity of the selected populations was evaluated by staining with anti-CD5-PE and 
anti-CD19-PE, followed by flow cytometric analysis. For adoptive transfer, 10 × 10
6
 TCL1 
leukemia cells were injected intraperitoneally into the syngeneic recipients. Two weeks after 
injection, mice were treated by oral gavage with the inhibitors for three weeks, as indicated. 
 
Two weeks later, on Day 15
th
 of post TCL1 adoptive transfer, 3 mg/kg/day Trametinib, 
30mg/kg/day Ibrutinib or both inhibitors were administered by oral gavage for 21 days. 
Animals were treated daily with the inhibitors, diluted in 200 μL of carrier solution.  
Flow cytometric analysis were performed on peripheral blood samples of the TCL1 mice, 
withdrawn from the tail vein. Analysis were performed during and on the last day of 
treatment. We observed that Trametinib was able to delay the expansion of leukemic cells 
both after 2 and 3 weeks of treatment, though not reaching a significant difference 
(p=0.0683). Ibrutinib alone was very efficient to delay the leukemia (p=0.0002) though no 
synergistic effects were observed when both inhibitors were used together (Figure 37). 
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Figure 37. TCL1 leukemic mice were treated for 21 days with 3 mg/kg/day Trametinib, 
30mg/kg/day Ibrutinib or both. Inhibitors were administered daily by oral gavage for 21 days. 
Left:CD5/CD19 positive B cells among each mouse group,  during treatment at day 15. Right: 
Leukemia follow-up before, during and after treatment completion. 
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5. DISCUSSION 
 
The ERK1/2 MAP kinase pathway is a central regulator of cell proliferation and controls 
both cell growth and cell cycle progression.  
Synthetic MEK1/2 inhibitors, which prevents activation of ERK1/ERK2, were reported to 
inhibit the proliferation of various cell types, including fibroblasts, T lymphocytes, smooth 
muscle cells, hepatocytes and epithelial cell lines (Dudley et al., 1995; Williams et al., 
1998; Sebolt-Leopold et al., 1999; Talarmin et al., 1999). Conversely, expression of 
constitutively active forms of MEK1 (Brunet et al., 1994; Seger et al., 1994) enhances the 
rate of cell proliferation. Small molecule inhibitors of MEK1/2 have been proposed that 
show activity in cell-based assays. Among these, Trametinib was recently approved as a 
single-agent by the FDA for the treatment of patients with BRAF mutated metastatic 
melanoma, in combination with BRAF inhibitors. 
CLL is a disease with anergic B cell characteristics, that is characterized by constitutive 
phosphorylation of ERK (Muzio et al, 2008; Apollonio et al, 2013). In this thesis, we 
sought to investigate whether MEK1/2 inhibitor Trametinib could be exploited to efficiently 
target CLL cells in vitro and in vivo.   Indeed we were able to show that trametinib is able to 
induce growth inhibition and cytotoxic effect in a number of leukemia and lymphoma cell 
lines which showed to be phosphor ERK positive. In aprticular Trametinib induced 
inhibition of cell growth, an increased G1 phase and a decreased S phase.  
To prove the specificity of the inhibition and the relevance of the MAPK pathway in 
sustaining proliferation and viability of leukemic cells, we were also able to show 
substantial cytotoxicity and decrease in proliferation, when siMEK1 and siMEK2 were used 
in MEC1 cells line to deplete Mek1 and Mek2. 
 
More importantly, we cultured primary human CLL cells expressing constitutive levels of 
pERK with effective dose of Trametinib, and observed a reduction in viability. 
Nevertheless, Trametinib efficacy was vey heterogeneous and interstingly it correlated with 
functional anergy of the cells and expression of phospho-ERK. Conversely, phospho-ERK 
negative CLL cells responded to a lesser degree to MEK inhibition. Positive and significant 
correlation was observed between ERK positivity and viability of the CLL cells, when 
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cultured with Trametinib. Higher levels of pERK positivity were associated with elevated 
cytotoxicity. This observation opens the interesting possibility of exploiting Trametinib as a 
new therapeutic option in CLL, at least in a subset of cases of the disease. To this end, the 
correlation with the levels of pERK suggest the possibility that a pre-therapy screening of 
the activation of the MAPK pathway may be proposed as a companion diagnostics for the 
use of MEK inhibitors in clinical trials exploring the use of such inhibitors. 
To further strengthen this observation, we were also able to evaluate the efficacy of 
Trametinib in vivo in the TCL1 transgenic mouse model of CLL. Our preliminary data 
suggests that MEK inhibition is able to delay the leukemia expansion in vivo, though not 
reaching significance, probably due to a limited number of animals utilized in this pilot 
study. At present, we are following the impact of Trametinib treatment on TCL1 mouse 
survival. 
In conclusion, during my stay at San Raffaele Institute, we preliminarily showed that in 
preclinical models (both in vitro and in vivo) a therapeutic effect can be observed when 
targeting the MAPK pathway, constitutively active in anergic B cells and in a subset of CLL 
patients. In particular, we showed that treatment with Trametinib significantly reduces the 
survival of a series of pERK(+) cell lines, human primary CLL and TCL1 mouse leukemic 
cells in vitro. We have also studied if Trametinib would potentiate the cytotoxic activity of 
BTK inhibitor Ibrutinib, both in vitro and in vivo, though with no success.  
These data further underscore the relevance of the anergic pathway as a potential therapeutic 
target in CLL. As these new therapeutic option will progressively be evaluated, the 
challenge going forward will be to find effective combinations of MEK1/2 inhibition with 
other inhibitors in order to improve the quality and the depth of the clinical responses, 
aiming for a final cure of the disease. 
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SUMMARY 
 
Chronic lymphocytic leukemia (CLL) represents the most common leukemia in the Western 
world. It is characterized by a neoplastic clonal expansion of CD5 B lymphocytes.  
 
Deletion of the chromosomal 13q14 is the most frequent chromosomal aberration in CLL, 
but how it contributes to CLL pathogenesis and outcome of disease is still unclear. miR-15a 
and miR-16-1, located in the 13q14 region, are important for regulating levels of  TP53 
transcript and protein, As TP53 is a negative regulator of TERT, the catalytic component of 
telomerase, we hypotized that levels of TERT, are correlated with levels of  miR-15a/16-1 
and TP53. During first part of my PhD thesis, we characterized CLL cases, with the sole 
13q14 deletion and with no chromosomal abnormalities, for miR-15a/16-1, TP53 and TERT 
expression. We found that levels of miR-15a and miR-16-1 were significantly lower in 
13q14del CLL than in CLL with no chromosomal abnormalities and both miRNAs levels 
inversely correlated with TP53 expression. TERT levels inversely correlated with TP53 
levels in 13q14del CLL, but not in CLL with normal cytogenetic profile and were 
significantly lower in the former group of CLL  than in the latter one.  Notably, disease 
progression was more rapid in both group of CLL with high TERT levels (>median), 
whereas high TP53 levels (>median) conferred better clinical outcome only in the subgroup 
of 13q14del CLL. Within the 13q14del CLL, TERT/ TP53 level profile identified subgroups 
of patients with different clinical outcomes. Within the 13q14del CLL, high TERT/low 
TP53 level profile is an independent marker of worse clinical outcome. Overall, these data 
indicate that in 13q14del CLL, the miR-15a/miR-16-1 and TP53 axis may be an important 
pathway regulating telomerase expression, and TERT/TP53 profile may be particularly 
useful in refining the prognosis of patients with 13q14del CLL.  
 
Relevant proportion of CLL patients show biochemical and functional features of anergic B 
cells, characterized by the lack of signalling capacity and constitutive activation of ERK1/2. 
Anergy is the mechanisms that the immune system adopts to silence autoreactive B 
lymphocytes. Therefore, it is reasonable to suggest that reversing the anergic state of these 
CLL might be beneficial in terms of clinical responses. 
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The aim of my PhD studies, regarding search for new therapeutic strategies, was to evaluate 
the therapeutic potential of agents that target ERK activity in CLL, in vitro and in vivo. 
MEK1/2 inhibitor Trametinib was recently approved as a single-agent for the treatment of 
metastatic melanoma.  During my stay at San Raffaele Institute, we preliminarily showed 
that in preclinical models (both in vitro and in vivo) a therapeutic effect can be observed 
when targeting the MAPK pathway, constitutively active in anergic B cells and in a subset 
of CLL patients. In particular, we showed that treatment with Trametinib significantly 
reduces the survival of a series of pERK(+) cell lines, human primary CLL and TCL1 
mouse leukemic cells in vitro. We have also studied if Trametinib would potentiate the 
cytotoxic activity of BTK inhibitor Ibrutinib, both in vitro and in vivo, though with no 
success. Our data underscored the relevance of the anergic pathway as a potential 
therapeutic target in CLL.  
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